Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity Treatment

Gastrointestinal Side Effects Raise Red Flags

Researchers presented findings on survodutide at a conference in New Orleans, highlighting its efficacy in weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) treatment. The study involved patients with obesity and MASLD. Results were shared in June.

Survodutide, a dual GLP-1/glucagon receptor agonist, has shown promise in addressing obesity and MASLD by promoting significant weight loss and improving liver health. The treatment works by mimicking natural hormones that regulate appetite and glucose metabolism.

Roughly one in five patients discontinued survodutide due to adverse events, primarily gastrointestinal issues such as nausea and vomiting. These side effects are common among GLP-1 receptor agonists, but their frequency and severity can impact treatment adherence.

Can Tolerability Issues be Mitigated?

The study's findings indicate that while survodutide is effective, its tolerability is a concern. Patients experienced significant weight loss, but the high dropout rate due to side effects may limit its long-term viability.

To improve treatment outcomes, researchers may need to explore strategies to minimize gastrointestinal side effects. This could involve adjusting dosing regimens or developing new formulations with improved tolerability profiles.

The consequences of survodutide's tolerability issues will be closely watched as the treatment moves forward. If left unaddressed, these concerns may hinder its adoption and limit its potential benefits for patients with obesity and MASLD.

Frequently Asked Questions

What is survodutide used for? Survodutide is being investigated as a treatment for obesity and MASLD, with promising results in promoting weight loss and improving liver health.

What are the most common side effects of survodutide? The most common side effects include gastrointestinal issues such as nausea and vomiting, which led to treatment discontinuation in roughly one in five patients.

How might survodutide's tolerability be improved? Researchers may explore strategies such as adjusting dosing regimens or developing new formulations to minimize gastrointestinal side effects and improve treatment adherence.